Previous 10 |
ArQule ( ARQL +3.3% ) is up on below-average volume in response to preliminary data on miransertib in patients with Proteus syndrome, an ultra-rare condition characterized by abnormal overgrowth of multiple tissue which changes the shape of body structures over time.The results were just...
Data support miransertib as a potential first systemic treatment for individuals affected by Proteus syndrome ArQule, Inc. (Nasdaq:ARQL), today announced the publication of clinical pharmacodynamic, safety and efficacy data in patients with Proteus syndrome. These data, together with da...
ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the fourth quarter and full year of 2018 before the market opens on Thursday, March 7, 2019. The Company will hold a conference call and webcast on the same day at 9:00 a.m. ET to discuss these results and provi...
ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Brian Schwartz, M.D., Chief Medical Officer and Head of Research and Development, of ArQule will present at the 8th Annual Leerink Partners Global Healthcare Conference on February 28, 2019, at 11:30 a...
Recently, the ArQule’s lead candidate, derazantinib, showed positive preliminary action from a Phase 2 liver cancer study. In addition, ArQule reported that partner Basilea Pharmaceutica (OTC: BPMUF ) will team up with Roche (OTCQX: RHHBY ) to assess the combination of derazantinib,...
ArQule (NASDAQ: ARQL ) announces that licensee Basilea Pharmaceutica ( OTC:BPMUF ) will collaborate with Roche ( OTCQX:RHHBY ) to evaluate the combination of BAL087 (derazantinib) (formerly ARQ087), a pan-fibroblast growth factor receptor (FGFR) kinase inhibitor, and Tecentriq (atezolizuma...
ArQule, Inc.’s (Nasdaq: ARQL) partner, Basilea Pharmaceutica Ltd. (SIX: BSLN), announced today that it entered into a collaboration with Roche (SIX: RO, ROG) to explore a combination of derazantinib (BAL087) and Roche’s PD-L1-blocking immune-checkpoint inhibitor, atezolizumab (...
News, Short Squeeze, Breakout and More Instantly...
What stock will go up the most in 2020? We'd all like to know that one. And it's a question that's a lot easier to ask than to answer. Let's start by looking at the top 10 stocks of 2019 for clues. The No. 1 stock of 2019, Axsome Therapeutics , had a staggering 3,578% retu...
Dollar Tree (NASDAQ: DLTR) stock was pummeled in November after its earnings report resulted in the deep discounter reducing its sales outlook for the third consecutive quarter and lowering its profit forecast. Shares trade at the same level now as they did a year ago, meaning inves...
The top 10 stocks of 2019 are an interesting group. You might think tech stocks would dominate the upper echelon of equities, but you'd be wrong. As we saw in the IPO market , individual healthcare stocks actually had the strongest returns last year. Seven biotech companies made our list, inc...